We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+0.05%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$3.55B
AUM Growth
+$59.4M
Cap. Flow
-$31.8M
Cap. Flow %
-0.9%
Top 10 Hldgs %
49.57%
Holding
665
New
156
Increased
155
Reduced
111
Closed
128
Avg Time Held Equity + Options
3.9 quarters
Top 10 Avg Time Held Equity + Options
0.8 quarters
Top 20 Avg Time Held Equity + Options
1.2 quarters
Avg Time Held Equity only
4.3 quarters
Top 10 Avg Time Held Equity only
0.8 quarters
Top 20 Avg Time Held Equity only
1.2 quarters

Top Buys

Rank Stock Value
1
HCP icon
HashiCorp, Inc. Class A Common Stock
HCP
+$138M
2
ETRN icon
Equitrans Midstream Corporation Common Stock
ETRN
+$131M
3
EDR icon
Endeavor Group Holdings, Inc.
EDR
+$127M
4
MRO icon
Marathon Oil Corporation
MRO
+$123M
5
CHX icon
ChampionX
CHX
+$98.3M

Top Sells

Rank Stock Value
1
PXD icon
Pioneer Natural Resource Co.
PXD
+$638M
2
CERE icon
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$51.2M
3
DFS icon
Discover Financial Services
DFS
+$45.1M
4
SCRM icon
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
+$18.4M
5
NSC icon
Norfolk Southern
NSC
+$17.7M

Sector Composition

Rank Sector Weight
1 Energy 26.53%
2 Technology 21.03%
3 Healthcare 14.68%
4 Industrials 8.19%
5 Miscellaneous 6.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NFLX icon
376
Netflix
NFLX
$293B
$337K 0.01%
5,000
-35,000
-88% -$2.19M
2023 Q4
2 quarters
LYV icon
377
PUT
Live Nation Entertainment
LYV
$39.7B
$336K 0.01%
215,400
-22,500
-9% -$2.13M
2023 Q3
3 quarters
CRDF icon
378
Cardiff Oncology
CRDF
$84M
$333K 0.01%
+150,000
New +$565K
2024 Q2
0 quarters
CRGX icon
379
DELISTED
CARGO Therapeutics
CRGX
$328K 0.01%
+20,000
New +$380K
2024 Q2
0 quarters
EXPE icon
380
Expedia Group
EXPE
$32.9B
$328K 0.01%
2,600
-27,400
-91% -$3.38M
2024 Q1
1 quarter
NERV icon
381
Minerva Neurosciences
NERV
$152M
$319K 0.01%
99,856
+212
+0.2% +$574
2023 Q3
3 quarters
SRPT icon
382
Sarepta Therapeutics
SRPT
$1.89B
$316K 0.01%
2,000
-4,813
-71% -$618K
2023 Q4
2 quarters
CGON icon
383
CG Oncology
CGON
$5.66B
$316K 0.01%
+10,000
New +$347K
2024 Q2
0 quarters
VSTM icon
384
Verastem
VSTM
$759M
$299K 0.01%
100,389
+54,157
+117% +$446K
2022 Q1
9 quarters
CYPH icon
385
Cypherpunk Technologies Inc
CYPH
$317M
$294K 0.01%
149,772
+42,360
+39% +$111K
2023 Q1
5 quarters
SNAP icon
386
Snap
SNAP
$10.5B
$291K 0.01%
+17,500
New +$251K
2024 Q2
0 quarters
SCYX icon
387
SCYNEXIS
SCYX
$40.6M
$291K 0.01%
18,160
+444
+3% +$6.86K
2022 Q2
8 quarters
TWLO icon
388
Twilio
TWLO
$44.5B
$284K 0.01%
5,000
-27,500
-85% -$1.62M
2024 Q1
1 quarter
BGS icon
389
PUT
B&G Foods
BGS
$195M
$282K 0.01%
117,500
– –
2023 Q1
5 quarters
CC icon
390
PUT
Chemours
CC
$2.05B
$279K 0.01%
+46,900
New +$1.23M
2024 Q2
0 quarters
F icon
391
PUT
Ford
F
$48.5B
$274K 0.01%
570,900
– –
2022 Q2
8 quarters
ALT icon
392
Altimmune
ALT
$508M
$266K 0.01%
40,000
-16,795
-30% -$124K
2023 Q4
2 quarters
OTLK icon
393
Outlook Therapeutics
OTLK
$146M
$266K 0.01%
+36,000
New +$289K
2024 Q2
0 quarters
AKTS icon
394
DELISTED
Akoustis Technologies Inc
AKTS
$264K 0.01%
+2,000,000
New +$753K
2024 Q2
0 quarters
LVS icon
395
PUT
Las Vegas Sands
LVS
$23.4B
$258K 0.01%
37,200
+15,400
+71% +$719K
2024 Q1
1 quarter
NGNE icon
396
Neurogene
NGNE
$528M
$258K 0.01%
+7,100
New +$250K
2024 Q2
0 quarters
ZURA icon
397
Zura Bio
ZURA
$383M
$257K 0.01%
+73,396
New +$299K
2024 Q2
0 quarters
STWD icon
398
PUT
Starwood Property Trust
STWD
$4.7B
$253K 0.01%
138,100
+72,500
+111% +$1.41M
2021 Q2
12 quarters
VERU icon
399
Veru
VERU
$41.9M
$252K 0.01%
29,922
– –
2023 Q4
2 quarters
ADPT icon
400
Adaptive Biotechnologies
ADPT
$4.23B
$238K 0.01%
65,745
– –
2022 Q1
9 quarters
14 15
16
17 18

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q2 2024 Portfolio in Review

As of Q2 2024, UBS O'Connor held 665 positions worth $3.55B, up 1.7% from $3.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

UBS O'Connor's Q2 2024 filing shows 156 new, 155 increased, 111 reduced and 128 closed positions. Its largest new stake was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M. The largest sale was Pioneer Natural Resource Co., an estimated $638M.

By sector, the portfolio is most concentrated in Energy at 27% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.

  • UBS O'Connor's largest Q2 2024 buy was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M.
  • UBS O'Connor added most to HashiCorp, Inc. Class A Common Stock in Q2 2024, an estimated $138M increase.
  • UBS O'Connor's biggest Q2 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $51.2M.
  • UBS O'Connor fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $638M.
  • UBS O'Connor's ten largest holdings make up 50% of its $3.55B portfolio in Q2 2024.
  • UBS O'Connor opened 156 new positions and closed 128 in Q2 2024.
  • UBS O'Connor's portfolio value rose 1.7% quarter-over-quarter to $3.55B.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.